Literature DB >> 2230845

Serial studies of evoked potentials and circulating lymphocyte subsets for multiple sclerosis: attempts to monitor progress.

H M Chapel1, M Small, S Gregory, W B Matthews.   

Abstract

A concurrent change in evoked potential measurements and quantitation of circulating T-suppressor (CD8) lymphocyte subpopulations might indicate increased subclinical disease activity. Eight untreated patients with clinically definite multiple sclerosis were monitored monthly for changes in the numbers of cells positive for CD8 markers, and hence in the ratio of CD4: CD8 positive cells. Such changes were found not to be associated with changes in evoked potentials or clinical status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230845     DOI: 10.1007/bf00314747

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  Evoked potentials to test a treatment of chronic multiple sclerosis.

Authors:  D C Anderson; G E Slater; R Sherman; M G Ettinger
Journal:  Arch Neurol       Date:  1987-12

2.  Somatosensory evoked responses in multiple sclerosis patients with varying sensory loss.

Authors:  N S Namerow
Journal:  Neurology       Date:  1968-12       Impact factor: 9.910

3.  Serial recording of visual and somatosensory evoked potentials in multiple sclerosis.

Authors:  W B Matthews; D G Small
Journal:  J Neurol Sci       Date:  1979-01       Impact factor: 3.181

4.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; O Acuto; C Poole; L Palley; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

5.  Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease.

Authors:  D W Paty; L Kastrukoff; N Morgan; L Hiob
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

6.  Exacerbation detection in multiple sclerosis by clinical and evoked potential techniques: a preliminary report.

Authors:  W Likosky; R S Elmore
Journal:  Adv Neurol       Date:  1982

7.  T cell subsets in multiple sclerosis. A longitudinal study of exacerbating-remitting cases.

Authors:  M A Bach; C Martin; P Cesaro; J F Eizenbaum; J D Degos
Journal:  J Neuroimmunol       Date:  1985 Feb-Mar       Impact factor: 3.478

8.  Lymphocyte subpopulations in patients with multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-02       Impact factor: 10.154

9.  Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period.

Authors:  S L Hauser; E L Reinherz; C J Hoban; S F Schlossman; H L Weiner
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

10.  Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?

Authors:  A J Thompson; J Brazil; C A Whelan; E A Martin; M Hutchinson; C Feighery
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.